2 Ablative RadioTherapy Treatments for Prostate Cancer

Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.

NCT Number	NCT04654338
Lead Sponsor	Sunnybrook Health Sciences Centre
Conditions	Prostate Cancer
Enrollment	30 participants
Start Date	2020-07-29
Primary Completion	2024-01-29 (estimated)
Study Completion	2028-07-29 (estimated)
Updated on ClinicalTrials.gov	2023-06-27